Pacific Biosciences Of California (PACB) Non-Current Deferred Tax Liability (2020 - 2022)

Pacific Biosciences Of California's Non-Current Deferred Tax Liability history runs 3 years deep, the most recent figure standing at $835000.0 for Q4 2022.

• On a quarterly basis, Non-Current Deferred Tax Liability changed 0.36% year-over-year to $835000.0 in Q4 2022; TTM through Dec 2022 was $835000.0, a 0.36% change from a year earlier, with the FY2022 full-year figure at $835000.0, changed 0.36% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $835000.0 in Q4 2022 per PACB's latest filing, from $838000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $838000.0 in Q4 2021 and bottomed at $786000.0 in Q4 2020.
• The 3-year median for Non-Current Deferred Tax Liability is $835000.0 (2022), against an average of $819666.7.
• Across the five-year window, Non-Current Deferred Tax Liability rose 6.62% in 2021 and slipped 0.36% in 2022, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $786000.0 in 2020, then gained by 6.62% to $838000.0 in 2021, then fell by 0.36% to $835000.0 in 2022.
• Per Business Quant, the three latest PACB Non-Current Deferred Tax Liability figures stand at $835000.0 (Q4 2022), $838000.0 (Q4 2021), and $786000.0 (Q4 2020).